We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves. Cox proportional models were used at univariate and multivariate analyses. We collected data from 224 patients with advanced RCC receiving cabozantinib as second- (113, 5%) or third-line (111, 5%) therapy. The median PFS was significantly higher in patients with BMI ≥ 25 (9.9 vs. 7.6 months, p < 0.001). The median OS was higher in the BMI ≥ 25 subgroup (30.7 vs. 11.0 months, p = 0.003). As third-line therapy, both median PFS (9.2 months vs. 3.9 months, p = 0.029) and OS (39.4 months vs. 11.5 months, p = 0.039) were longer in patients with BMI ≥ 25. BMI was a significant predictor for both PFS and OS at multivariate analysis. We showed that a BMI ≥ 25 correlates with longer survival in patients receiving cabozantinib. BMI can be easily assessed and should be included in current prognostic criteria for advanced RCC.
Diagnostics (Basel, Switzerland). 2021 Jan 18*** epublish ***
Matteo Santoni, Francesco Massari, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia, Angelo Martignetti, Mimma Rizzo, Giacomo Cartenì, Enrique Grande, Marc R Matrana, Simon J Crabb, Nuno Vau, Giulia Sorgentoni, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli
Oncology Unit, Macerata Hospital, Via Santa Lucia 2, 62100 Macerata, Italy., Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy., Medical and Translational Oncology Unit, Department of Oncology, AziendaOspedaliera Santa Maria, 05100 Terni, Italy., Department of Medical Oncology, Istituto Nazionale dei Tumori IRCCS, 20133 Milan, Italy., Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust (AOUI Verona), P.le L.A. Scuro 10, 37134 Verona, Italy., Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy., Department of Medical Oncology, Istituto Oncologico Veneto IOV IRCCS, 35128 Padova, Italy., Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy., Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy., Dipartimento Oncologico USL Sud-Est Toscana-Area Senese, Località Campostaggia s.n.c., 53036 Poggibonsi, Italy., Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, 27100 Pavia, Italy., Department of Medical Oncology, AO "A. Cardarelli", 80131 Naples, Italy., Department of Medical Oncology, MD Anderson Cancer Center, 28033 Madrid, Spain., Department of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, LA 70121, USA., Southampton Clinical Trials Unit, University of Southampton, Southampton SO16 5AF, UK., Urologic Oncology, Champalimaud Clinical Center, 1400-038 Lisbon, Portugal., Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, 60126 Ancona, Italy.